Aureus Pharma Extends its Knowledge Database Agreement with Sanofi-Aventis R&D
News Nov 06, 2009
Aureus Pharma has announces the extension of its knowledge database agreement with sanofi-aventis research & development for an additional three-year term.
Under the agreement, Aureus will provide new AurSCOPE® knowledge databases and continue to update existing databases for sanofi-aventis' R&D division. The Aureus Pharma databases will give sanofi-aventis researchers access to information on major therapeutic targets. These include GPCR protein receptors, nuclear receptors, kinase inhibitors, ion channels, as well as information relative to drug safety including data on ADME (absorption, distribution, metabolism, and excretion).
The new agreement reinforces the relationship between Aureus Pharma and sanofi-aventis, which has been in existence for seven years already. It also secures additional revenues for Aureus over the next three years.
"Sanofi-aventis' decision to extend the partnership for an additional three year period, as well as to acquire new knowledge bases, confirms the fact that Aureus' products are meeting the needs of the world's leading pharmaceutical companies," said Dr Jason Theodosiou, CEO of Aureus Pharma.
Aureus Pharma's information solutions are working for many of the world's most successful biopharmaceutical companies and prestigious research institutions.
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
Algorithm Speeds Up Medical Image Analysis 1000 TimesNews
Medical image registration is a common technique that involves overlaying two images, such as magnetic resonance imaging (MRI) scans, to compare and analyze anatomical differences in great detail. Researchers have described a machine-learning algorithm that can register brain scans and other 3-D images more than 1,000 times more quickly using novel learning techniques.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE